ClinicalTrials.gg
Active, not recruitingNCT04337684Updated Mar 2, 2026

Long Term Follow-up on Menkes Disease Patients

An observational study in Menkes Disease, sponsored by Sentynl Therapeutics, Inc.. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Sentynl Therapeutics, Inc. (part of Zydus Lifesciences Limited) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

This study will collect long term follow-up data regarding overall survival and neurological parameters from patients previously identified and/or enrolled in Protocols 09-CH-0059 and 90-CH0149 and Historical Control data on Menkes disease patients.

Read the detailed description

Primary Objective:

  1. To provide additional clinical and safety data on long term following administration of Copper Histidinate treatment in patients treated with Copper Histidinate under Protocols 09-CH-0059 and 90-CH0149 and untreated patients previously identified and/or enrolled in Protocol 09-CH-0059.
  2. To provide additional Historical Control data on Menkes disease patients.
02

Conditions studied

  • Menkes Disease
03

In context

Lead sponsor

Sentynl Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

First submitted after Sentynl Therapeutics, Inc. became part of Zydus Lifesciences Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

  1. Any subject previously identified and/or enrolled in either Protocols 09-CH-0059 or 90-CH-0149.
  2. Any new untreated Menkes disease patient born after 1999.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject must have been previously identified and/or enrolled under Protocols 09-CH-0059 or 90-CH-0149; or An untreated Menkes disease patients for whom data collection is incomplete under Protocols 09-CH-0059 (Amendment M); or Other untreated Menkes disease patients.
  • Must sign and date an form by parent or legal guardian for this study prior to any assessment being done in this study. If the patient is > 18 years of age, the patient must sign the informed consent.
  • Male or female, aged 0 to \< 65 years of age.

Exclusion criteria

Exclusion Criteria:

- Unwillingness/unable to participate in the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Historical Control
  • Treated with Copper Histidinate

    Drug: Long Term Follow-Up

Interventions

  • DrugLong Term Follow-Up

    Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data. During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up.

    Also known as: CUTX-101

06

What researchers measure

Primary outcomes

  1. Long Term Follow-Up on Survival

    The primary outcome measure will be overall survival.

    Time frame: 12/01/2019 - 12/31/2022

07

Study locations

1 site
  • Sentynl Therapeutics
    Solana Beach, California 92117, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Feb 2026, 74 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2020
First posted
Apr 8, 2020
StartActual
Dec 1, 2019
Primary completionActual
Feb 26, 2026
CompletionEst.
Aug 31, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04337684
Responsible party
Sponsor
First posted
Apr 8, 2020
Start date
Dec 1, 2019
Primary completion
Feb 26, 2026
Completion
Aug 31, 2026 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion